Details for Patent: 8,906,851
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,906,851 protect, and when does it expire?
Patent 8,906,851 protects FARXIGA, BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in three NDAs.
Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-three patent family members in twenty-four countries.
Summary for Patent: 8,906,851
Title: | Method for treating diabetes |
Abstract: | Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA.sub.1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided. |
Inventor(s): | Fineman; Mark (San Diego, CA), MacConell; Leigh (San Diego, CA), Taylor; Kristin (San Diego, CA) |
Assignee: | Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE) |
Application Number: | 13/708,474 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,906,851
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-001 | Jan 8, 2014 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE | See Plans and Pricing | ||||
Astrazeneca Ab | FARXIGA | dapagliflozin | TABLET;ORAL | 202293-002 | Jan 8, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE | See Plans and Pricing | ||||
Astrazeneca Ab | BYDUREON | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-001 | Jan 27, 2012 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,906,851
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2006283517 | See Plans and Pricing | |||
Australia | 2011200663 | See Plans and Pricing | |||
Australia | 2013205769 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |